Skip to main content

Advertising Disclaimer »

Main menu

  • Journals
    • Pediatrics
    • Hospital Pediatrics
    • Pediatrics in Review
    • NeoReviews
    • AAP Grand Rounds
    • AAP News
  • Authors/Reviewers
    • Submit Manuscript
    • Author Guidelines
    • Reviewer Guidelines
    • Open Access
    • Editorial Policies
  • Content
    • Current Issue
    • Online First
    • Archive
    • Blogs
    • Topic/Program Collections
    • AAP Meeting Abstracts
  • Pediatric Collections
    • COVID-19
    • Racism and Its Effects on Pediatric Health
    • More Collections...
  • AAP Policy
  • Supplements
  • Multimedia
    • Video Abstracts
    • Pediatrics On Call Podcast
  • Subscribe
  • Alerts
  • Careers
  • Other Publications
    • American Academy of Pediatrics

User menu

  • Log in
  • My Cart

Search

  • Advanced search
American Academy of Pediatrics

AAP Gateway

Advanced Search

AAP Logo

  • Log in
  • My Cart
  • Journals
    • Pediatrics
    • Hospital Pediatrics
    • Pediatrics in Review
    • NeoReviews
    • AAP Grand Rounds
    • AAP News
  • Authors/Reviewers
    • Submit Manuscript
    • Author Guidelines
    • Reviewer Guidelines
    • Open Access
    • Editorial Policies
  • Content
    • Current Issue
    • Online First
    • Archive
    • Blogs
    • Topic/Program Collections
    • AAP Meeting Abstracts
  • Pediatric Collections
    • COVID-19
    • Racism and Its Effects on Pediatric Health
    • More Collections...
  • AAP Policy
  • Supplements
  • Multimedia
    • Video Abstracts
    • Pediatrics On Call Podcast
  • Subscribe
  • Alerts
  • Careers

Discover Pediatric Collections on COVID-19 and Racism and Its Effects on Pediatric Health

American Academy of Pediatrics
Article

Hospitalization for Influenza A Versus B

Dat Tran, Wendy Vaudry, Dorothy Moore, Julie A. Bettinger, Scott A. Halperin, David W. Scheifele, Taj Jadvji, Liza Lee, Teresa Mersereau and for the members of the Canadian Immunization Monitoring Program Active
Pediatrics September 2016, 138 (3) e20154643; DOI: https://doi.org/10.1542/peds.2015-4643
Dat Tran
aDivision of Infectious Diseases, Department of Paediatrics, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wendy Vaudry
bDivision of Infectious Diseases, Department of Paediatrics, Stollery Children’s Hospital, University of Alberta, Edmonton Alberta, Canada;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dorothy Moore
cDivision of Infectious Diseases, Department of Paediatrics, Montreal Children’s Hospital, McGill University, Montreal, Québec, Canada;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Julie A. Bettinger
dVaccine Evaluation Center, BC Children’s Hospital, University of British Columbia, Vancouver, British Columbia, Canada;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Scott A. Halperin
eCanadian Center for Vaccinology, IWK Health Centre, Dalhousie University, Halifax, Nova Scotia, Canada;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David W. Scheifele
dVaccine Evaluation Center, BC Children’s Hospital, University of British Columbia, Vancouver, British Columbia, Canada;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Taj Jadvji
fSection of Infectious Diseases, Department of Paediatrics, Alberta Children’s Hospital, University of Calgary, Calgary, Alberta, Canada; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Liza Lee
gCentre for Immunization & Respiratory Infectious Diseases, Public Health Agency of Canada, Ottawa, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Teresa Mersereau
gCentre for Immunization & Respiratory Infectious Diseases, Public Health Agency of Canada, Ottawa, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • Comments
Loading

Article Figures & Data

Tables

  • Additional Files
    • View popup
    TABLE 1

    Distribution of Hospital Admissions by Influenza Type and Season

    Influenza TypeSeasona
    2004–2005 (n = 392)2005–2006 (n = 373)2006–2007 (n = 368)2007–2008 (n = 496)2008–2009 (n = 378)2010–2011 (n = 671)2011–2012 (n = 588)2012–2013 (n = 889)2004–2013 (n = 4155)Matched B Seasonsb (n = 2320)Mismatched B Seasonsc (n = 1835)
    Influenza A272 (69.4)231 (61.9)311 (84.5)313 (63.1)197 (52.1)451 (67.2)245 (41.7)625 (70.3)2645 (63.7%)1659 (71.5)986 (53.7)
    Influenza B120 (30.6)142 (38.1)57 (15.5)183 (36.9)181 (47.9)220 (32.8)343 (58.3)264 (29.7)1510 (36.3%)661 (28.5)849 (46.3)
    • ↵a Data are n (column %) unless otherwise indicated.

    • ↵b 2004–2005, 2006–2007, 2010–2011, 2012–2013.

    • ↵c 2005–2006, 2007–2008, 2008–2009, 2011–2012.

    • View popup
    TABLE 2

    Characteristics of Hospitalized Patients by Influenza Type

    CharacteristicsInfluenza Typea
    Influenza A (n = 2645)Influenza B (n = 1510)Unadjusted OR/P
    Boys1554 (58.8)875 (57.9)0.97 (0.85–1.10)
    Age, y
     Mean (SD)3.4 (3.9)5.0 (4.3)<.0001
     Median (IQR)2.0 (0.6–4.8)3.9 (1.4–7.2)<.0001
    Age group<.0001
     0–5 mo586 (22.2)170 (11.3)—
     6–23 mo749 (28.3)305 (20.2)—
     24–59 mo681 (25.7)423 (28.0)—
     5–9 y406 (15.3)401 (26.6)—
     ≥10 y223 (8.4)211 (14.0)—
    Health status.0004
     No underlying condition1342 (50.7)684 (45.3)—
     Vaccine-indicated condition976 (36.9)651 (43.1)—
     Other underlying condition327 (12.4)175 (11.6)—
    Ethnic originb
     White532/845 (63.0)337/591 (57.0)—
     Asian92/845 (10.9)60/591 (10.2)—
     Middle Eastern51/845 (6.0)45/591 (7.6)—
     Black49/845 (5.8)74/591 (12.5)—
     Latin American17/845 (2.0)11/591 (1.9)—
     Aboriginal81/845 (9.6)46/591 (7.8)—
     Other/mixed23/845 (2.7)18/591 (3.0)—
     Data not available675419—
    Influenza vaccination statusc
     Received influenza vaccine98/1504 (6.5)59/855 (6.9)—
     Data not available555485—
    • —, Inferential statistical analysis was not conducted.

    • ↵a Data are n (column %) unless otherwise indicated; where fractions are shown, denominator is the number of cases with data available.

    • ↵b Data available only for 2008–2009 season onward; n = 1520 (influenza A), n = 1010 (influenza B).

    • ↵c Includes children ≥6 mo; n = 2059 (influenza A), n = 1340 (influenza B).

    • View popup
    TABLE 3

    Signs and Symptoms of Hospitalized Patients by Influenza Type

    Sign or SymptomaInfluenza Typeb
    Seasonal A (n = 2142)Influenza B (n = 1248)Unadjusted ORAdjusted ORc
    Systemic
     Fever1990 (92.9)1167 (93.5)1.10 (0.83–1.46)—
     Headache78 (3.6)123 (9.9)2.89 (2.16–3.88)1.85 (1.36–2.52)
     Lethargy741 (34.6)465 (37.3)1.12 (0.97–1.30)—
    Respiratory
     Coryza1277 (59.6)744 (59.6)1.00 (0.87–1.15)—
     Cough1835 (85.7)1051 (84.2)0.89 (0.73–1.08)—
     Wheezing476 (22.2)260 (20.8)0.92 (0.78–1.09)—
     Respiratory distress904 (42.2)489 (39.2)0.88 (0.76–1.02)—
     Apnea65 (3.0)37 (3.0)0.98 (0.65–1.47)—
    Extrarespiratory
     Abdominal pain119 (5.6)126 (10.1)1.91 (1.47–2.48)1.38 (1.05–1.81)
     Vomiting and/or diarrhea and/or dehydration1003 (46.8)569 (45.6)0.95 (0.83–1.10)—
     Myalgia38 (1.8)102 (8.2)4.93 (3.37–7.20)3.19 (2.16–4.72)
     Arthralgia10 (0.5)15 (1.2)2.59 (1.16–5.79)1.95 (0.86–4.40)
     Seizure238 (11.1)116 (9.3)0.82 (0.65–1.04)—
    • —, adjusted OR was not calculated.

    • ↵a Individuals had >1 sign or symptom and percentages do not add up to 100%.

    • ↵b Data are n (column %) unless otherwise indicated; data available only for 2006–2007 season onward.

    • ↵c Adjusted for age group and health status.

    • View popup
    TABLE 4

    Treatment and Illness Severity of Hospitalized Patients by Influenza Type

    TreatmentInfluenza Typea
    Seasonal A (n = 2645)Influenza B (n = 1510)Unadjusted OR/PAdjusted OR/Pb
    Antiviral
     Antibiotic400/2643 (15.1)202/1508 (13.4)0.87 (0.72–1.04)—
     Measures of illness severity1913/2640 (72.5)1050/1508 (69.6)0.87 (0.76–1.00)—
    Respiratory complications
     Croup101 (3.8)51 (3.4)0.88 (0.62–1.24)—
     Pneumonia (radiologically confirmed)595 (22.5)364 (24.1)1.09 (0.94–1.27)—
    Extrarespiratory complications
     Myositis18 (0.7)101 (6.7)10.46 (6.31–17.35)6.95 (4.15–11.64)
     Myocarditis6 (0.2)6 (0.4)1.75 (0.56–5.45)—
     Hepatitis24 (0.9)22 (1.5)1.61 (0.90–2.89)—
     Meningitis6 (0.2)4 (0.3)1.17 (0.33–4.15)—
     Encephalitis42 (1.6)36 (2.4)1.51 (0.97–2.37)—
     Length of hospital stay, median (IQR), d3.0 (2.0–5.0)3.0 (2.0–5.0)0.60—
    Mortality
     Attributable to influenza10 (0.4)16 (1.1)2.82 (1.28–6.23)2.65 (1.18–5.94)
     All-cause10 (0.4)18 (1.2)3.18 (1.46–6.90)2.95 (1.34–6.49)
     Admitted to ICU337 (12.7)190 (12.6)0.99 (0.82–1.19)—
     Required mechanical ventilationc212 (62.9)124 (65.3)1.11 (0.76–1.61)—
     Required extracorporeal membrane oxygenationc7 (2.1)6 (3.2)1.54 (0.51–4.64)—
     Length of ICU stay, median (IQR), dc3.0 (1.0–6.5)3.0 (1.0–7.0)0.62—
    • —, adjusted OR or P was not calculated.

    • ↵a Data are n (column %) unless otherwise indicated; where fractions are shown, denominator is the number of cases with data available.

    • ↵b Adjusted for age group and health status.

    • ↵c Denominator of the percentage is the number of ICU admitted cases.

    • View popup
    TABLE 5

    Factors Associated With Radiologically Confirmed Pneumonia in Patients Hospitalized With Influenza B

    Radiologically Confirmed Pneumonia
    Univariate Analysis (n = 1510)Multivariable Analysisa (n = 1510)
    OR (95% CI)POR (95% CI)P
    Boys0.94 (0.74–1.20).63——
    Age, y0.98 (0.95–1.01).13——
    Age group<.0001<.0001
     0–5 moReferenceReference
     6–23 mo3.29 (1.94–5.57)<.00012.88 (1.69–4.91)<.0001
     24–59 mo3.33 (2.00–5.54)<.00012.66 (1.58–4.47).0002
     5–9 y1.75 (1.03–2.98).041.40 (0.82–2.40).22
     ≥10 y2.03 (1.15–3.60).011.48 (0.82–2.66).19
    Health status<.0001<.0001
     No underlying conditionReferenceReference
     Vaccine-indicated condition1.95 (1.51–2.52)<.00011.93 (1.47–2.51)<.0001
     Other underlying condition1.27 (0.85–1.90).251.25 (0.83–1.89).28
    • —, sex and age (in years) were not included in the multivariable model.

    • ↵a Multivariable model included age group and health status as independent variables.

    • View popup
    TABLE 6

    Factors Associated With ICU Admission in Patients Hospitalized With Influenza B

    Univariate Analysis (n = 1510)Univariate Analysis by Health Statusa
    No Underlying Condition (n = 684)Vaccine-Indicated Conditionb (n = 651)Other Underlying Condition (n = 175)
    OR (95% CI)POR (95% CI)POR (95% CI)POR (95% CI)P
    Boys1.13 (0.83–1.54).44—c—c—c—c—c—c
    Age, y1.03 (0.99–1.06).10—c—c—c—c—c—c
    Age group.05.01.13.59
     0–5 moReferenceReference—Reference—Reference—
     6–23 mo1.28 (0.70–2.35).423.46 (1.26–9.49).020.33 (0.11–0.96).040.43 (0.11–1.70).23
     24–59 mo1.46 (0.82–2.58).202.64 (0.95–7.35).060.47 (0.18–1.21).120.62 (0.17–2.26).47
     5–9 y0.97 (0.53–1.77).921.70 (0.57–5.01).340.29 (0.11–0.78).010.57 (0.16–2.08).40
     ≥10 y1.91 (1.04–3.54).045.79 (1.91–17.57).0020.41 (0.15–1.13).081.13 (0.29–4.44).86
    Health status.002
     No underlying conditionReference—d—d—d—d—d—d
     Vaccine-indicated condition1.68 (1.20–2.35).003—d—d—d—d—d—d
     Other underlying condition2.00 (1.25–3.21).004—d—d—d—d—d—d
    • ↵a Conducted due to detection of an interaction between age group and health status (P = .045) on multivariable analysis.

    • ↵b For the 0–5 mo age group, a vaccine-indicated condition refers to an underlying condition for which influenza vaccination is particularly recommended in individuals aged ≥6 mo, and does not indicate that influenza vaccination should be given to this age group.

    • ↵c Sex and age (in years) were not included in the multivariable model.

    • ↵d N/A.

Additional Files

  • Tables
  • Data Supplement

    • Supplemental Information
PreviousNext
Back to top

Advertising Disclaimer »

In this issue

Pediatrics
Vol. 138, Issue 3
1 Sep 2016
  • Table of Contents
  • Index by author
View this article with LENS
PreviousNext
Email Article

Thank you for your interest in spreading the word on American Academy of Pediatrics.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Hospitalization for Influenza A Versus B
(Your Name) has sent you a message from American Academy of Pediatrics
(Your Name) thought you would like to see the American Academy of Pediatrics web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Request Permissions
Article Alerts
Log in
You will be redirected to aap.org to login or to create your account.
Or Sign In to Email Alerts with your Email Address
Citation Tools
Hospitalization for Influenza A Versus B
Dat Tran, Wendy Vaudry, Dorothy Moore, Julie A. Bettinger, Scott A. Halperin, David W. Scheifele, Taj Jadvji, Liza Lee, Teresa Mersereau, for the members of the Canadian Immunization Monitoring Program Active
Pediatrics Sep 2016, 138 (3) e20154643; DOI: 10.1542/peds.2015-4643

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Hospitalization for Influenza A Versus B
Dat Tran, Wendy Vaudry, Dorothy Moore, Julie A. Bettinger, Scott A. Halperin, David W. Scheifele, Taj Jadvji, Liza Lee, Teresa Mersereau, for the members of the Canadian Immunization Monitoring Program Active
Pediatrics Sep 2016, 138 (3) e20154643; DOI: 10.1542/peds.2015-4643
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Print
Download PDF
Insight Alerts
  • Table of Contents

Jump to section

  • Article
    • Abstract
    • Methods
    • Results
    • Discussion
    • Conclusions
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • Comments

Related Articles

  • PubMed
  • Google Scholar

Cited By...

  • Influenza vaccination: protecting the most vulnerable
  • Recommendations for Prevention and Control of Influenza in Children, 2020-2021
  • Recommendations for Prevention and Control of Influenza in Children, 2019-2020
  • Recommendations for Prevention and Control of Influenza in Children, 2019-2020
  • When "B" becomes "A": the emerging threat of influenza B virus
  • Development of Influenza B Universal Vaccine Candidates Using the "Mosaic" Hemagglutinin Approach
  • Antibody Responses toward the Major Antigenic Sites of Influenza B Virus Hemagglutinin in Mice, Ferrets, and Humans
  • Recommendations for Prevention and Control of Influenza in Children, 2018-2019
  • A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Study To Investigate the Safety, Tolerability, and Pharmacokinetics of an Anti-Influenza B Virus Monoclonal Antibody, MHAB5553A, in Healthy Volunteers
  • Chimeric Hemagglutinin Constructs Induce Broad Protection against Influenza B Virus Challenge in the Mouse Model
  • Google Scholar

More in this TOC Section

  • Differences in Lifetime Earning Potential for Pediatric Subspecialists
  • Health Services Use by Children in the Welfare System Who Died by Suicide
  • Changes in Family Poverty Status and Child Health
Show more Article

Similar Articles

Subjects

  • Infectious Disease
    • Infectious Disease
    • Influenza
    • Vaccine/Immunization
  • Journal Info
  • Editorial Board
  • Editorial Policies
  • Overview
  • Licensing Information
  • Authors/Reviewers
  • Author Guidelines
  • Submit My Manuscript
  • Open Access
  • Reviewer Guidelines
  • Librarians
  • Institutional Subscriptions
  • Usage Stats
  • Support
  • Contact Us
  • Subscribe
  • Resources
  • Media Kit
  • About
  • International Access
  • Terms of Use
  • Privacy Statement
  • FAQ
  • AAP.org
  • shopAAP
  • Follow American Academy of Pediatrics on Instagram
  • Visit American Academy of Pediatrics on Facebook
  • Follow American Academy of Pediatrics on Twitter
  • Follow American Academy of Pediatrics on Youtube
  • RSS
American Academy of Pediatrics

© 2021 American Academy of Pediatrics